Latest Conference Articles

In a presentation for the American Psychiatric Association, Elinore McCance-Katz says helpline calls have dramatically increased since the COVID-19 pandemic.

Substance use is common in as many as 10% of pregnant women in the US. What are the risks of each substances, and what are the proven methods of treatment?

How do comorbidities influence patients' life expectancies? What is the role of public health programs?

Why the field lacks behind in effective diagnostic tools, which could better inform tailored therapy.

The novel target therapy has reported promising early findings. What is its potential?

In a presentation at the APA Spring Highlights Meeting 2020, Patrice Harris, MD, says telemedicine is crucial to maintain care while decreasing the risk of COVID-19.

How have natural-cause mortality rates changed over time in an international population?

How psychiatry can catch up to other specialties in accurate, timely diagnostics based on molecular breakthrough.

It might be particularly difficult for psychiatrists to treat trauma patients through telehealth means.

David Jiang, MD, explains some preffered therapies and medications for trauma patients.

Data regarding major adverse events remain unreliable due to a lack of a patient registry.

A public health expert shares insight on the positives and pitfalls learned from stigma-reduction campaigns.

A discussion on how difficulties accepting the drug addiction public health crisis is affecting the rate of care-seeking patients.

Discussing research related to TAVR with a cardiac surgeon from Brigham and Women's Hospital.

Discussing takeaways from the late-breaking abstracts related to TAVR presented at ACC.20/WCC with a cardiac surgeon from Brigham and Women's Hospital.

The latest piece coming to us through Notes from Rounds examines how the timing of hormone replacement therapy can impact potential for adverse outcomes.

How do e-cigarettes fit into the cardiovascular health paradigm? What more needs to be learned?

New findings show the addition of easily identified circulating proteins can provide a more accurate risk assessment.

A discussion on how the COVID-19 outbreak might impact burnout among cardiologists and other medical professionals.

Discussing a study examining rates of burnouts in cardiology with lead investigator Laxmi Mehta, MD, director of preventative cardiology and women’s cardiovascular health at Ohio State University.

A look at the state of cardiometabolic care based on research at ACC.20/WCC from a fourth-year medical student.

How new DAPA-HF findings continue to build the SGLT2 inhibitors' cardiovascular portfolio.

Breaking down the details of the E3 trial, and what more needs to be found in the follow-up.

Patients of both sexes and differing levels of LVEF reported similar reductions in NT-proBNP when treated with the combination therapy, versus lone valsartan.

An interventional cardiologist shares perspective on what the new two-year TAVR findings mean for him and colleagues.

New secondary analsysis from the large-scale heart failure trial shows continued benefit of the SGLT2 inhibitor.

Discussing a REDUCE-IT substudy presented at ACC.20/WCC examining the impact of various EPA levels on outcomes seen in REDUCE-IT.

Results of the TICO study support use of ticagrelor monotherapy for patients with ACS requiring PCI with drug-eluting stents.